T cells control the generation of nanomolar-affinity anti-glycan antibodies

Journal of Clinical Investigation

Volumn 127, Issue 4, 2017, Pages 1491-1504

  Polonskaya, Zinaida ^a   Deng, Shenglou ^b   Sarkar, Anita ^a   Kain, Lisa ^a   Comellas Aragones, Marta ^a   McKay, Craig S ^c   Kaczanowska, Katarzyna ^a   Holt, Marie ^a   McBride, Ryan ^a   Palomo, Valle ^a   Self, Kevin M ^a   Taylor, Seth ^b   Irimia, Adriana ^a   Mehta, Sanjay R ^d,e   Dan, Jennifer M ^d,f   Brigger, Matthew ^d,g   Crotty, Shane ^d,f   Schoenberger, Stephen P ^f   Paulson, James C ^a   Wilson, Ian A ^a   Savage, Paul B ^b   Finn, M G ^c   Teyton, Luc ^a   more..

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b Brigham Young University   (United States)

^c GEORGIA INSTITUTE OF TECHNOLOGY   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^f LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

^g RADY CHILDREN'S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; COMPLEMENTARY DNA; GLYCAN; GLYCAN ANTIBODY; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2B; IMMUNOGLOBULIN G3; IMMUNOGLOBULIN M; OLIGOSACCHARIDE; PNEUMOCOCCUS VACCINE; Q BETA OLIGOSACCHARIDE; QBETA TS14 CONJUGATE; TETRASACCHARIDE; UNCLASSIFIED DRUG; BACTERIAL POLYSACCHARIDE; BACTERIAL PROTEIN; BACTERIUM ANTIBODY; GLYCOPEPTIDE; PROTEIN BINDING; VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CHILD; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNOLOGICAL MEMORY; MOLECULAR RECOGNITION; MOUSE; NONHUMAN; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; SECONDARY IMMUNIZATION; SEROTYPE; STREPTOCOCCUS PNEUMONIAE; T LYMPHOCYTE; VACCINE PRODUCTION; VIRUS LIKE AGENT; ADULT; AMINO ACID SEQUENCE; ANIMAL; ANTIBODY AFFINITY; BLOOD; C57BL MOUSE; CHEMISTRY; HYBRIDOMA; IMMUNOLOGY; KNOCKOUT MOUSE; MALE; MOLECULAR MODEL; NONOBESE DIABETIC MOUSE; PNEUMOCOCCAL INFECTIONS; SCID MOUSE; VACCINATION; X RAY CRYSTALLOGRAPHY;

ADULT; AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, BACTERIAL; ANTIBODY AFFINITY; B-LYMPHOCYTES; BACTERIAL PROTEINS; CD4-POSITIVE T-LYMPHOCYTES; CHILD; CRYSTALLOGRAPHY, X-RAY; FEMALE; GLYCOPEPTIDES; HUMANS; HYBRIDOMAS; IMMUNOGLOBULIN G; MALE; MICE, INBRED C57BL; MICE, INBRED NOD; MICE, KNOCKOUT; MICE, SCID; MODELS, MOLECULAR; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; POLYSACCHARIDES, BACTERIAL; PROTEIN BINDING; STREPTOCOCCUS PNEUMONIAE; VACCINATION; VACCINE POTENCY;

EID: 85018687367     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI91192     Document Type: Article

References (83)

1. Astronomo RD, Burton DR. Carbohydrate vaccines: developing sweet solutions to sticky situations? Nat Rev Drug Discov. 2010;9(4):308-324.
2. Trotter CL, et al. Optimising the use of conjugate vaccines to prevent disease caused by Haemophilus influenzae type b, Neisseria meningitidis and Streptococcus pneumoniae. Vaccine. 2008;26(35):4434-4445.
3. Durando P, Faust SN, Fletcher M, Krizova P, Torres A, Welte T. Experience with pneumococcal polysaccharide conjugate vaccine (conjugated to CRM197 carrier protein) in children and adults. Clin Microbiol Infect. 2013;19(suppl 1):1-9.
4. Bonten MJ, et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med. 2015;372(12):1114-1125.
5. Weintraub A. Immunology of bacterial polysaccharide antigens. Carbohydr Res. 2003;338(23):2539-2547.
6. Mond JJ, Lees A, Snapper CM. T cellindependent antigens type 2. Annu Rev Immunol. 1995;13:655-692.
7. Beuvery EC, van Rossum F, Nagel J. Comparison of the induction of immunoglobulin M and G antibodies in mice with purified pneumococcal type 3 and meningococcal group C polysaccharides and their protein conjugates. Infect Immun. 1982;37(1):15-22.
8. Mitchison NA. The carrier effect in the secondary response to hapten-protein conjugates. II. Cellular cooperation. Eur J Immunol. 1971;1(1):18-27.
9. Amanna IJ, Carlson NE, Slifka MK. Duration of humoral immunity to common viral and vaccine antigens. N Engl J Med. 2007;357(19):1903-1915.
10. Lee YC, et al. Haemophilus influenzae type b vaccine failure in children is associated with inadequate production of high-quality antibody. Clin Infect Dis. 2008;46(2):186-192.
11. Ekström N, et al. Kinetics and avidity of antibodies evoked by heptavalent pneumococcal conjugate vaccines PncCRM and PncOMPC in the Finnish Otitis Media Vaccine Trial. Infect Immun. 2005;73(1):369-377.
12. Usinger WR, Lucas AH. Avidity as a determinant of the protective efficacy of human antibodies to pneumococcal capsular polysaccharides. Infect Immun. 1999;67(5):2366-2370.
13. Cygler M, Rose DR, Bundle DR. Recognition of a cell-surface oligosaccharide of pathogenic Salmonella by an antibody Fab fragment. Science. 1991;253(5018):442-445.
14. Villeneuve S, et al. Crystal structure of an anti-carbohydrate antibody directed against Vibrio cholerae O1 in complex with antigen: molecular basis for serotype specificity. Proc Natl Acad Sci U S A. 2000;97(15):8433-8438.
15. Vyas NK, et al. Molecular recognition of oligosaccharide epitopes by a monoclonal Fab specific for Shigella flexneri Y lipopolysaccharide: X-ray structures and thermodynamics. Biochemistry. 2002;41(46):13575-13586.
16. Harris SL, Fernsten P. Thermodynamics and density of binding of a panel of antibodies to high-molecular-weight capsular polysaccharides. Clin Vaccine Immunol. 2009;16(1):37-42.
17. Oberli MA, et al. Molecular analysis of carbohydrate-antibody interactions: case study using a Bacillus anthracis tetrasaccharide. J Am Chem Soc. 2010;132(30):10239-10241.
18. Theillet FX, et al. Dynamic aspects of antibody: oligosaccharide complexes characterized by molecular dynamics simulations and saturation transfer difference nuclear magnetic resonance. Glycobiology. 2011;21(12):1570-1579.
19. Haji-Ghassemi O, Blackler RJ, Young NM, Evans SV. Antibody recognition of carbohydrate epitopes. Glycobiology. 2015;25(9):920-952.
20. Bai L, et al. Natural killer T (NKT)-B-cell interactions promote prolonged antibody responses and long-term memory to pneumococcal capsular polysaccharides. Proc Natl Acad Sci U S A. 2013;110(40):16097-16102.
21. Ishioka GY, et al. MHC interaction and T cell recognition of carbohydrates and glycopeptides. J Immunol. 1992;148(8):2446-2451.
22. Deck B, Elofsson M, Kihlberg J, Unanue ER. Specificity of glycopeptide-specific T cells. J Immunol. 1995;155(3):1074-1078.
23. Harding CV, Kihlberg J, Elofsson M, Magnusson G, Unanue ER. Glycopeptides bind MHC molecules and elicit specific T cell responses. J Immunol. 1993;151(5):2419-2425.
24. Pellicci DG, et al. Recognition of ?-linked self glycolipids mediated by natural killer T cell antigen receptors. Nat Immunol. 2011;12(9):827-833.
25. Deck MB, Sjölin P, Unanue ER, Kihlberg J. MHC-restricted, glycopeptide-specific T cells show specificity for both carbohydrate and peptide residues. J Immunol. 1999;162(8):4740-4744.
26. Mogemark M, Cirrito TP, Sjölin P, Unanue ER, Kihlberg J. Influence of saccharide size on the cellular immune response to glycopeptides. Org Biomol Chem. 2003;1(12):2063-2069.
27. Kabat EA. The upper limit for the size of the human antidextran combining site. J Immunol. 1960;84:82-85.
28. Verez-Bencomo V, et al. A synthetic conjugate polysaccharide vaccine against Haemophilus influenzae type b. Science. 2004;305(5683):522-525.
29. Adamo R, Nilo A, Castagner B, Boutureira O, Berti F, Bernardes GJ. Synthetically defined glycoprotein vaccines: current status and future directions. Chem Sci. 2013;4(8):2995-3008.
30. Bendelac A, Savage PB, Teyton L. The biology of NKT cells. Annu Rev Immunol. 2007;25:297-336.
31. Liu Y, et al. A modified ?-galactosyl ceramide for staining and stimulating natural killer T cells. J Immunol Methods. 2006;312(1-2):34-39.
32. Carnaud C, et al. Cutting edge: cross-talk between cells of the innate immune system: NKT cells rapidly activate NK cells. J Immunol. 1999;163(9):4647-4650.
33. Hermans IF, et al. Dendritic cell function can be modulated through cooperative actions of TLR ligands and invariant NKT cells. J Immunol. 2007;178(5):2721-2729.
34. Galli G, et al. Invariant NKT cells sustain specific B cell responses and memory. Proc Natl Acad Sci U S A. 2007;104(10):3984-3989.
35. Andrews NJ, et al. Serotype-specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: a postlicensure indirect cohort study. Lancet Infect Dis. 2014;14(9):839-846.
36. Fattom A, Matalon A, Buerkert J, Taylor K, Damaso S, Boutriau D. Efficacy profile of a bivalent Staphylococcus aureus glycoconjugated vaccine in adults on hemodialysis: phase III randomized study. Hum Vaccin Immunother. 2015;11(3):632-641.
37. Romero-Steiner S, Frasch CE, Carlone G, Fleck RA, Goldblatt D, Nahm MH. Use of opsonophagocytosis for serological evaluation of pneumococcal vaccines. Clin Vaccine Immunol. 2006;13(2):165-169.
38. Stowell SR, et al. Microbial glycan microarrays define key features of host-microbial interactions. Nat Chem Biol. 2014;10(6):470-476.
39. Esposito S, et al. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine compared to those of a 7-valent pneumococcal conjugate vaccine given as a three-dose series with routine vaccines in healthy infants and toddlers. Clin Vaccine Immunol. 2010;17(6):1017-1026.
40. Bentley SD, et al. Genetic analysis of the capsular biosynthetic locus from all 90 pneumococcal serotypes. PLoS Genet. 2006;2(3):e31.
41. Safari D, et al. Identification of the smallest structure capable of evoking opsonophagocytic antibodies against Streptococcus pneumoniae type 14. Infect Immun. 2008;76(10):4615-4623.
42. Benaissa-Trouw B, Lefeber DJ, Kamerling JP, Vliegenthart JF, Kraaijeveld K, Snippe H. Synthetic polysaccharide type 3-related di-, tri-, and tetrasaccharide-CRM(197) conjugates induce protection against Streptococcus pneumoniae type 3 in mice. Infect Immun. 2001;69(7):4698-4701.
43. Hong V, Presolski SI, Ma C, Finn MG. Analysis and optimization of copper-catalyzed azidealkyne cycloaddition for bioconjugation. Angew Chem Int Ed Engl. 2009;48(52):9879-9883.
44. Low JG, et al. Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine: results from a double-blinded, randomized Phase I clinical trial in healthy Asian volunteers. Vaccine. 2014;32(39):5041-5048.
45. Yin Z, et al. Boosting immunity to small tumor-associated carbohydrates with bacteriophage q? capsids. ACS Chem Biol. 2013;8(6):1253-1262.
46. Briles DE, Crain MJ, Gray BM, Forman C, Yother J. Strong association between capsular type and virulence for mice among human isolates of Streptococcus pneumoniae. Infect Immun. 1992;60(1):111-116.
47. McHeyzer-Williams M, Okitsu S, Wang N, McHeyzer-Williams L. Molecular programming of B cell memory. Nat Rev Immunol. 2011;12(1):24-34.
48. Colino J, Shen Y, Snapper CM. Dendritic cells pulsed with intact Streptococcus pneumoniae elicit both protein-and polysaccharidespecific immunoglobulin isotype responses in vivo through distinct mechanisms. J Exp Med. 2002;195(1):1-13.
49. Giudicelli V, et al. IMGT/LIGM-DB, the IMGT comprehensive database of immunoglobulin and T cell receptor nucleotide sequences. Nucleic Acids Res. 2006;34(Database issue):D781-D784.
50. Scherer EM, Zwick MB, Teyton L, Burton DR. Difficulties in eliciting broadly neutralizing anti-HIV antibodies are not explained by cardiolipin autoreactivity. AIDS. 2007;21(16):2131-2139.
51. Alam SM, et al. Role of HIV membrane in neutralization by two broadly neutralizing antibodies. Proc Natl Acad Sci U S A. 2009;106(48):20234-20239.
52. van der Woude MW, Bäumler AJ. Phase and antigenic variation in bacteria. Clin Microbiol Rev. 2004;17(3):581-611.
53. Connolly ML. Solvent-accessible surfaces of proteins and nucleic acids. Science. 1983;221(4612):709-713.
54. Jegerlehner A, Maurer P, Bessa J, Hinton HJ, Kopf M, Bachmann MF. TLR9 signaling in B cells determines class switch recombination to IgG2a. J Immunol. 2007;178(4):2415-2420.
55. Breitfeld D, et al. Follicular B helper T cells express CXC chemokine receptor 5, localize to B cell follicles, and support immunoglobulin production. J Exp Med. 2000;192(11):1545-1552.
56. Crotty S. T follicular helper cell differentiation, function, and roles in disease. Immunity. 2014;41(4):529-542.
57. Avci FY, Li X, Tsuji M, Kasper DL. A mechanism for glycoconjugate vaccine activation of the adaptive immune system and its implications for vaccine design. Nat Med. 2011;17(12):1602-1609.
58. Day CL, et al. Ex vivo analysis of human memory CD4 T cells specific for hepatitis C virus using MHC class II tetramers. J Clin Invest. 2003;112(6):831-842.
59. Landais E, et al. New design of MHC class II tetramers to accommodate fundamental principles of antigen presentation. J Immunol. 2009;183(12):7949-7957.
60. Iwasaki A, Medzhitov R. Regulation of adaptive immunity by the innate immune system. Science. 2010;327(5963):291-295.
61. Leadbetter EA, et al. NK T cells provide lipid antigen-specific cognate help for B cells. Proc Natl Acad Sci U S A. 2008;105(24):8339-8344.
62. Chang PP, et al. Identification of Bcl-6-dependent follicular helper NKT cells that provide cognate help for B cell responses. Nat Immunol. 2011;13(1):35-43.
63. Hua Z, Hou B. TLR signaling in B-cell development and activation. Cell Mol Immunol. 2013;10(2):103-106.
64. Kasturi SP, et al. Programming the magnitude and persistence of antibody responses with innate immunity. Nature. 2011;470(7335):543-547.
65. Jennings GT, Bachmann MF. The coming of age of virus-like particle vaccines. Biol Chem. 2008;389(5):521-536.
66. Cavallari M, et al. A semisynthetic carbohydrate-lipid vaccine that protects against S. pneumoniae in mice. Nat Chem Biol. 2014;10(11):950-956.
67. Broecker F, et al. Synthetic lipoteichoic acid glycans are potential vaccine candidates to protect from clostridium difficile infections. Cell Chem Biol. 2016;23(8):1014-1022.
68. Wedemayer GJ, Patten PA, Wang LH, Schultz PG, Stevens RC. Structural insights into the evolution of an antibody combining site. Science. 1997;276(5319):1665-1669.
69. Baxendale HE, Davis Z, White HN, Spellerberg MB, Stevenson FK, Goldblatt D. Immunogenetic analysis of the immune response to pneumococcal polysaccharide. Eur J Immunol. 2000;30(4):1214-1223.
70. Dal Porto JM, Haberman AM, Shlomchik MJ, Kelsoe G. Antigen drives very low affinity B cells to become plasmacytes and enter germinal centers. J Immunol. 1998;161(10):5373-5381.
71. Wu H, et al. Ultra-potent antibodies against respiratory syncytial virus: effects of binding kinetics and binding valence on viral neutralization. J Mol Biol. 2005;350(1):126-144.
72. Maynard JA, et al. Protection against anthrax toxin by recombinant antibody fragments correlates with antigen affinity. Nat Biotechnol. 2002;20(6):597-601.
73. Ekström N, Väkeväinen M, Verho J, Kilpi T, Käyhty H. Functional antibodies elicited by two heptavalent pneumococcal conjugate vaccines in the Finnish Otitis Media Vaccine Trial. Infect Immun. 2007;75(4):1794-1800.
74. Tian H, Weber S, Thorkildson P, Kozel TR, Pirofski LA. Efficacy of opsonic and nonopsonic serotype 3 pneumococcal capsular polysaccharide-specific monoclonal antibodies against intranasal challenge with Streptococcus pneumoniae in mice. Infect Immun. 2009;77(4):1502-1513.
75. Ramsland PA, Farrugia W, Bradford TM, Mark Hogarth P, Scott AM. Structural convergence of antibody binding of carbohydrate determinants in Lewis Y tumor antigens. J Mol Biol. 2004;340(4):809-818.
76. Nagae M, et al. Crystal structure of anti-polysialic acid antibody single chain Fv fragment complexed with octasialic acid: insight into the binding preference for polysialic acid. J Biol Chem. 2013;288(47):33784-33796.
77. Lemieux RU. How water provides the impetus for molecular recognition in aqueous solution. Acc Chem Res. 1996;29(8):373-380.
78. Adachi O, et al. Targeted disruption of the MyD88 gene results in loss of IL-1-and IL-18-mediated function. Immunity. 1998;9(1):143-150.
79. Yamamoto M, et al. Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway. Science. 2003;301(5633):640-643.
80. Madsen L, et al. Mice lacking all conventional MHC class II genes. Proc Natl Acad Sci U S A. 1999;96(18):10338-10343.
81. Berger M, Moresco EMY, Beutler BA. Mutagenetix Database. UT Southwestern Medical Center Web site. http://mutagenetix.utsouthwestern. edu/. Updated February 8, 2017. Accessed February 8, 2017.
82. Mallet-Designe VI, Stratmann T, Homann D, Carbone F, Oldstone MB, Teyton L. Detection of low-avidity CD4+ T cells using recombinant artificial APC: following the antiovalbumin immune response. J Immunol. 2003;170(1):123-131.
83. Lefranc MP, et al. IMGT unique numbering for immunoglobulin and T cell receptor variable domains and Ig superfamily V-like domains. Dev Comp Immunol. 2003;27(1):55-77.